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Abstract Interstitial lung disease and pulmonary hyperten-
sion (PH) are the most common cardiopulmonary findings
in patients with systemic sclerosis (SSc). About two thirds
of patients suffering from SSc develop scleroderma
interstitial lung disease. PH is present in about 20% of
SSc patients and is typically associated with severe lung
disease, although it may be an isolated manifestation of
SSc. High-resolution CT scanning is a key method for
evaluating chest involvement. There are four roles of
imaging in scleroderma interstitial lung disease: 1) detec-
tion of lung involvement, 2) identification of patients likely
to respond to treatment, 3) assessment of treatment efficacy,
and 4) exclusion of other significant diseases to include PH
and cardiac and esophageal abnormalities.
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Introduction
Systemic sclerosis (SSc), or scleroderma, is a chronic
multisystem disorder of small vessels and connective
tissues characterized by diffuse fibrosis of the skin and
internal organs, most frequently the lungs and gastrointes-
tinal tract. The disease has a 3:1 female predilection and
typically occurs in the third to fifth decades of life. Almost
all patients have skin involvement. Up to 80% of patients have
limited cutaneous disease, which typically has an insidious
onset and skin changes confined to the face and extremities,
whereas 20% with diffuse involvement may have more severe
and rapidly progressive skin, lung, cardiac, and gastrointestinal
disease [1]. Patients with interstitial lung disease (ILD) and
pulmonary vascular disease may be severely symptomatic due
to restrictive lung physiology and low diffusing capacity.
Esophageal dysmotility occurs in almost all SSc patients, and
gastroesophageal reflux may mimic or overlap with ILD.
Cardiac involvement, to include right heart dysfunction due to
pulmonary hypertension (PH), myocardial fibrosis, and
pericardial involvement, may further compound pulmonary
symptoms.
ILD and PH are the most common cardiopulmonary
findings in SSc [2, 3]. About two thirds of patients suffering
from SSc develop scleroderma ILD (SILD) [4–6]. PH is
present in about 20% of SSc patients and is typically
associated with severe pulmonary disease, although it may
be an isolated manifestation of SSc [2]. Currently, SILD is the
leading cause of death in SSc patients, due to pulmonary
fibrosis with or without PH. The mortality rate from SILD is
about 40% within 10 years after the onset of the disease [7–9].
There are four key roles of imaging in ILD related to
SSc: 1) detection of lung involvement, 2) identification of
patients likely to respond to treatment, 3) assessment of
treatment efficacy, and 4) exclusion of other significant
diseases to include PH and cardiac and esophageal
abnormalities.
Detection
Chest radiography is highly insensitive in detecting and
assessing the extent of lung involvement in SSc patients
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DOI 10.1007/s11926-010-0095-0[10]. In fact, patients with pulmonary symptoms and early
lung involvement may have a normal chest radiograph.
Radiographic findings of SILD are observed in up to two
thirds of symptomatic patients, whereas pulmonary fibrosis
is detected in only 25% to 44% [11]. SILD typically
manifests as low lung volume and predominantly increased
ground glass opacity (GGO) and reticular interstitial
thickening that is greatest in the lung bases. Advanced
cases with pulmonary fibrosis may exhibit traction bron-
chiectasis and honeycomb cystic change. However, some
patients with pulmonary fibrosis may have subtle radio-
graphic findings [10, 11].
High-resolution CT (HRCT) has been shown to be more
accurate than chest radiography in detecting and character-
izing diffuse lung diseases, and abnormalities on CT
correlate more closely with pulmonary function test (PFT)
abnormalities [12–14]. HRCT is now well-established as a
sensitive and noninvasive means of detecting and charac-
terizing SILD [15–19]. CT features of fibrosis are present in
55% to 65% of all patients with SSc and in up to 96% of
those with abnormal PFT results [5, 11, 13, 14, 17, 19, 20].
As a result, HRCT has become an important part of the
routine evaluation of SILD. Classically, the disease affects
juxtapleural, posterior, and basilar portions of the lungs,
with initially subtle alterations of increased GGO, defined
as increased lung attenuation in the absence of architectural
distortion, as well as accentuated reticular markings that
may progress to pulmonary fibrosis, defined as architectural
distortion with reticular intralobular interstitial thickening,
traction bronchiectasis and bronchiolectasis, and honey-
comb cystic change (Figs. 1 and 2). These hallmark CT
features of SILD are similar to those of idiopathic,
nonspecific interstitial pneumonitis (NSIP). A similar
association has been reported in radiologic-pathologic
correlations of surgical lung biopsy specimens of patients
with SSc [20–23].
SILD typically manifests on CT as predominantly GGO
with an admixture of pulmonary fibrosis consistent with the
NSIP pattern. Honeycomb cystic changes are reported in 11%
to 37% of patients with SILD. This is unlike other patients
with NSIP, who have little or no cystic change [23–25]. As
honeycomb cystic change is typically a marker for usual
interstitial pneumonia (UIP) and pulmonary fibrosis [26],
these findings suggest that patients with SILD disease may
have a mixture (or overlap) of UIP and NSIP patterns. This
is consistent with the findings of Desai et al. [16] and other
autopsy studies, in which typical histopathologic findings of
SILD included marked pulmonary fibrosis and honeycomb
cystic change [24, 27, 28].
It has been incorrectly assumed that SILD is more
common and severe in patients with diffuse cutaneous
systemic sclerosis (dcSSc). In several recent studies, about
40% of patients with pulmonary involvement have demon-
strated cutaneous systemic sclerosis (lcSSc) [8, 9, 29, 30••].
In the recent Scleroderma Lung Study, lcSSc and dcSSc
patients were indistinguishable with regard to their baseline
pulmonary functions, but lcSSc patients presented with
more extensive pulmonary fibrosis, possibly reflecting a
delay in diagnosis and progression of lung disease prior to
study entry [30••]. The rate of progression of SILD is
similar in lcSSc and dcSSc patients after adjustment for
baseline differences in the degree of pulmonary fibrosis.
Given that baseline forced vital capacity and pulmonary
fibrosis scores were the most important independent
predictors of the decline in pulmonary function over time
in Scleroderma Lung Study patients, all SSc patients should
be evaluated carefully for lung involvement irrespective of
disease extent [29].
Criteria have been developed for scoring the severity and
extent of SILD disease based on disease distribution,
relative proportions of reticulations and GGO, and presence
of fibrosis on CT scans at one or more levels throughout the
Fig. 1 Coronal and sagittal
chest CT reconstructions (lung
window) demonstrate the classic
appearance of early lung
involvement in scleroderma
interstitial lung disease. Initially
subtle alterations of increased
ground glass opacity and
accentuated reticular markings
(a and b) that affect the
peripheral, posterior, and basilar
portions of the lungs
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quantification schema. Visual scoring systems typically
divide each lung into three zones (lung apex to aortic arch,
aortic arch to inferior pulmonary veins, inferior pulmonary
veins to lung bases), and the extent of lung abnormality in
each zone is scored on a scale of 0–4 (0 = absent; 1=1%–
25%; 2=26%–50%; 3=51%–75%; 4=76%–100%) [31].
More recently, a simplified scoring system based on whether
more or less than 25% of the lung is affected has been
suggested[32••]. Computer-based approaches also have been
investigated and are based on measurement of the density or
texture features of each pixel and assignment of a measure of
the amount of abnormal lung tissue present. Computer-based
models correlate well with visual scoring techniques for the
detection of fibrosis (area under the curve = 0.86) and with
the assessment of extent of disease (area under the curve =
0.96 for estimating lung involvement >25%) without the
intrareader variation encountered with visual scoring [33].
Prediction
HRCT scanning has been used to predict outcome in
addition to characterizing the nature and extent of SILD
[34–36]. The absence of lung disease at an initial CT
evaluation is a superior predictor of excellent long-term
prognosis with regard to SILD. In a serial HRCT study of
90 SSc patients, 40 had no evidence of pulmonary fibrosis
on an initial scan; of these 40, 35 (88%) continued to have a
normal HRCT scan at follow-up for an average of 5 years
[15]. Because many SSc patients have limited pulmonary
fibrosis that may not necessarily progress, the decision to
start treatment is often a clinical challenge. The estimation
of disease extent (using HRCT) and severity (using PFT) is
pivotal. Careful prognostic evaluation, including the staging
of disease severity and the definition of longitudinal disease
behavior (by serial imaging and PFT), is central to the
formulation of a logical management plan [21].
It is now well-established that GGO is not indicative of
active inflammation and likely represents microscopic
pulmonary fibrosis that is below the resolution of CT.
Previously, the presence of GGO in the absence of
associated architectural distortion was thought to represent
underlying inflammation, or “alveolitis,” and to predict a
high likelihood of reversible lung disease in SSc, based on
studies in other diffuse lung diseases [13]. Recent studies
have shown that at best, a weak relationship between GGO
and abnormal bronchoalveolar lavage evidence for active
lung inflammation [37]. Furthermore, the limitations of
GGO as a predictive marker of active or reversible
inflammation have been reinforced by longitudinal studies
of CT change with and without treatment. When reticular
interstitial abnormalities are present, as in most SSc cases,
regression of disease on CT occurs in only a minority of
patients in the short term [38]. In the long term, GGO
usually progresses to overt fibrosis [16]. In a recent serial
study of 41 SSc patients, GGO that occurred in two thirds
of the cases regressed in only 5% during the following
2 years and was often resistant to treatment [38]. Thus, the
postulated relationship between GGO and active inflamma-
tion/alveolitis in SILD has been largely discredited.
More recently, the findings of fibrosis on HRCT scans of
patients with SILD have been shown to be a useful
predictor of the progression of fibrosis when untreated
and of a favorable response to treatment with cyclophos-
phamide compared with placebo [36]. The extent of
pulmonary fibrosis on CT also has played a key role in
determining the prognosis of patients with SSc [32••]. In a
study of 215 patients, those with more extensive disease on
HRCT (i.e., abnormalities involving >20% of the lung
volume) had strikingly higher mortality and rapid decline of
lung function, whereas patients with less than 20%
Fig. 2 Coronal and sagittal
chest CT reconstructions (lung
window) demonstrate the classic
appearance of scleroderma
interstitial lung disease in
patients with progressive
disease, showing extensive
architectural distortion due to
progressive pulmonary
fibrosis (a and b)
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pared with SSc patients with a normal HRCT [32••]. To
overcome the difficulties in formally scoring disease extent
on HRCT in routine practice, the authors proposed a simple
semiquantitative staging system of limited and extensive
disease, in which CT evaluation and forced vital capacity
values are integrated.
Treatment Outcomes
Experience is limited with the use of HRCT as an outcome
measure in therapeutic trials. HRCT scanning has been used
only infrequently in a prospective, systematic manner as an
outcome parameter for assessing therapeutic responses in
patients with SILD [39–43]. The validity of serial CT
studies is also compromised by the difficulty in achieving
exact anatomic comparability between initial and follow-up
CT scans, which is due to inherent differences in HRCT
slice acquisitions. Low-dose volume (spiral) acquisition CT
techniques may overcome this problem, and several studies
are under way. In contrast, when anatomic comparability is
achieved, it may be difficult to ascertain the clinical
significance of minor CT changes that are confined to
limited lung regions. The recent serial study of Launay et
al. [15] was limited by their definition of change in lung
involvement by more or less than 50% of the lung volume.
This system may fail to identify significant change in many
cases in which the arbitrary threshold of 50% is not crossed.
In a more recent study, when readers graded SILD on serial
HRCT as worsened, unchanged, or improved, there was an
excellent correlation among CT changes, patient outcome,
and treatment efficacy that was only marginal as suggested
by conventional pulmonary function criteria [43].
Other Significant Thoracic Diseases
PH, defined as pulmonary artery pressure greater than 35 mm
Hg as estimated by transesophageal echocardiography, affects
about20%(range,6%–60%)ofpatientswithSSc[2, 3]a n di s
a major cause of SSc-related death [44••]. When complicated
by PH, systemic sclerosis has a very poor prognosis. About
half of patients with PH develop the disease within 5 years of
the SSc diagnosis [44••]. Primary cardiac involvement from
SSc may smolder for years before manifesting as overt
cardiomyopathy, pericardial disease, or conduction abnor-
malities [45]. SSc heart disease has a poor prognosis and
may be related to excessive deposition of abnormal collagen
that impairs myocardial contractility, and to ischemia from
coronary vasculopathy [46].
Scleroderma involves the gastrointestinal tract in up to
90% of patients, and fibrosis and atrophy may result in
motility disorders. Esophageal involvement is often an
early and asymptomatic manifestation of SSc. A dilated
esophagus containing fluid, gas, and/or debris in the setting
of SSc reflects esophageal involvement and may help
differentiate ILD due to connective tissue disease from
other etiologies (Fig. 3). Asymptomatic esophageal dilata-
tion and esophageal dysmotility are detected in up to 80%
of patients [47]. Gastroesophageal reflux may play a role in
the development and/or progression of SILD [48, 49]. Early
detection and treatment of esophageal involvement may
forestall complications, which include chronic reflux,
aspiration pneumonia, Barrett’s esophagus, and esophageal
stricture and malignancy.
The presence of mediastinal lymph node enlargement in
patients with SILD is relatively higher than other causes of
ILD and has been reported in up to 60% of cases [50].
Nodal enlargement typically corresponds to reactive change
on histopathology when biopsy is performed.
Conclusions
Scleroderma is a systemic disorder of connective tissues
and vasculopathy that involves multiple organ systems,
typically the skin, esophagus, and lungs. Symptoms of ILD
may frequently overlap with those of PH, aspiration
pneumonia, and cardiomyopathy. As patients with limited
and diffuse cutaneous scleroderma may exhibit progressive
and extensive pulmonary fibrosis, all scleroderma patients
Fig. 3 Esophageal dilatation with retained debris is an early and
frequent manifestation of scleroderma and may help differentiate
interstitial lung disease due to connective tissue disease from that of
other etiologies
Curr Rheumatol Rep (2010) 12:156–161 159should be evaluated for lung involvement. Histopathologic
assessment of SILD typically represents overlapping fea-
tures with NSIP and UIP.
HRCT, in conjunction with PFT results, plays a critical
role in the detection and treatment of SILD and in the
prediction of outcomes. Visual scoring and computer-based
HRCT techniques are comparable in detecting and grading
disease severity and progression. On CT, SILD typically
manifests as GGO and accentuated reticulations that may
progress to pulmonary fibrosis. GGO was recently dis-
credited as a marker of active inflammation and reversible
lung injury.
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